20 de dezembro de 2020

This article summarises the main recommendations of the new guideline. Request PDF on ResearchGate On Jan 1, 2013, Dinesh Khanna and others published American College of Rheumatology guidelines for management of gout, Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian … Oxford University Press is a department of the University of Oxford. It is also frequently associated with co-morbidities such as diabetes mellitus, depression, cardiovascular disease, and chronic pulmonary diseases. The BSR guidelines also suggest that uric acid-lowering therapy should be offered to patients following a second attack of gout or if a further attack occurs within a year as opposed to the more than three attacks a year quoted in the article. Khanna D, FitzGerald JD, Khanna PP et al. Common dysfunctional variants in the ABC G2 urate transporter may be important causes of early onset gout in Japanese males [113] and in Han Chinese [114] but evidence from twin studies in the USA suggests that while genetic factors have an important influence on serum urate levels and hyperuricaemia, lifestyle and environmental factors are more important risk factors for primary gout, outside the context of the rare single gene disorders [115]. This guideline contains several important changes from the 2007 BSR/BHPR guideline [2]. The updated EULAR and BSR guidelines advise that ULT should be considered and discussed with every patient from the first presentation. Roughley MJ, Belcher J, Mallen CD, Roddy E. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. In double blind RCTs, allopurinol given in a fixed dose of 300 mg daily was more effective than placebo [126] but less effective than febuxostat 80 mg or 120 mg daily [126, 127]. Read the most up-to-date coronavirus advice Find out more. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Perez-Ruiz F, Herrero-Beites AM, Carmona L. Euser SM, Hofman A, Westendorp RGJ, Breteler MMB. 2,5 In particular, the benefits, harms and limitations of drug therapy should be discussed. A systematic review published in 2012 [77] attempted to assess the risk, but as the number of studies was small, it concluded that there was insufficient evidence to recommend the discontinuation of diuretics across all indications in patients with gout. Sriranganathan MK, Vinik O, Falzon L et al. There is growing evidence regarding the importance of education in gout. Saunders 2012. 1. Febuxostat is generally well tolerated and can be used in doses of 80 mg or 120 mg daily in elderly patients [140] and others with mild to moderate renal impairment (GFR >30 ml/min/1.73 m2). General advice. Published by: British Society for Rheumatology. Such systemic therapy is also appropriate for oligo or polyarticular attacks of gout, In patients with acute gout where response to monotherapy is insufficient, combinations of treatment can be used, Interleukin-1 (IL-1) inhibitors may be considered in patients who have previously not responded adequately to standard treatment of acute gout (although not approved by the National Institute for Health and Care Excellence [NICE]), If diuretic drugs are being used to treat hypertension rather than heart failure, an alternative antihypertensive agent can be considered as long as blood pressure is controlled, All patients with gout should be given verbal and written information about the following: the causes and consequences of gout and hyperuricaemia; how to manage acute attacks; lifestyle advice about diet, alcohol consumption and obesity; and the rationale, aims and use of ULT to target urate levels. Genome-wide association studies have identified a number of genes coding for urate anion transporters expressed in the proximal renal tubular epithelium, but these account for <5% of the variation in serum urate [14]. Search results Jump to search results. Starting regime of allopurinol according to glomerular filtration rate. On the 26 th May 2017, the British Society for Rheumatology released an important update to their most ‘in demand’ clinical guideline, on the Management of Gout.Gout is the most searched for term on the BSR website and it’s is a particularly painful form of arthritis which is becoming more common, yet continues to be poorly managed. Michelle Hui, Alison Carr, Stewart Cameron, Graham Davenport, Michael Doherty, Harry Forrester, Wendy Jenkins, Kelsey M. Jordan, Christian D. Mallen, Thomas M. McDonald, George Nuki, Anthony Pywell, Weiya Zhang, Edward Roddy, for the British Society for Rheumatology Standards, Audit and Guidelines Working Group, The British Society for Rheumatology Guideline for the Management of Gout, Rheumatology, Volume 56, Issue 7, July 2017, Pages e1–e20, https://doi.org/10.1093/rheumatology/kex156. Gout is the most common cause of inflammatory arthritis worldwide, with 1–2 in every 100 people estimated to be affected by gout. Other national and regional guidelines include the US Agency for Healthcare Research and Quality's 2014 guidelines for Diagnosis of Gout and Management of Gout [37, 38], and the Australian and New Zealand [39] and Portuguese [40] recommendations for the diagnosis and management of gout that arose from the 3e initiative [36]. Although a small RCT has shown that commencement of allopurinol during an acute attack was not associated with a significant increase in daily pain, recurrent flares or inflammatory markers [116], the working group thought that postponing detailed discussion of long term ULT until a time when the patient was no longer in pain would allow the information to be better absorbed. The recommendation to rest acutely affected joints is based on widespread patient experience and expert opinion. The importance of screening for co-morbidities is highlighted by a recent population-based study that has demonstrated gout to be an independent risk factor for mortality from coronary heart disease and renal disease [94]. Ottaviani S, Richette P, Allard A, Ora J, Bardin T. Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Johnson ES, Smith DH, Thorp ML, Yang X, Juhaeri J. Marchini GS, Sarkissian C, Tian D, Gebreselassie S, Monga M. Jinnah HA, De GL, Harris JC, Nyhan WL, O'Neill JP. is or has been principle investigator on trials paid for by Pfizer, Novartis, Ipsen, Teijin and Menarini, received consulting or speakers fees from Pfizer, Novartis, Takeda, Shire and Lundbeck and their department holds research grants from Novartis, Pfizer, Amgen, lpsen, Teijin and Menarini. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. In another 6-month placebo-controlled RCT in patients initiating allopurinol at a dose of 100 mg od followed by up-titration in 100 mg increments, flares occurred in 33% of patients given colchicine 500 μg bd for flare prophylaxis compared with 77% of those treated with placebo [167]. a. What are the potential patient and healthcare professional barriers to management of patients with gout? Vitamin C supplements in this modest dose only have a very weak uricosuric effect in people with gout, which is insufficient for it to be used as substitute monotherapy for allopurinol or other licensed ULT. 9. The identification of monosodium urate crystals in joint and tissue samples remains the gold standard for the diagnosis of gout. It was clear that general practices did not employ the treat to target strategy. The British Society for Rheumatology/British Health Professionals in Rheumatology (BSR/BHPR) first published a guideline for the management of gout in 2007. Gout is the most common form of inflammatory arthritis and its incidence in the UK has steadily increased from 1.5% in 1997 to 2.5% in 2012. Rasburicase, a recombinant Aspergillus flavus uricase that is licensed for the treatment and prophylaxis of tumour lysis syndrome, but not for gout, has also been used successfully in some patients with severe refractory gout [184] despite its greater potential immunogenicity. COVID-19 in rheumatoid arthritis cases: an Iranian referral center experience. Description and guidelines for prevention in patients with renal insufficiency, Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout, Relation between adverse events associated with allopurinol and renal function in patients with gout, Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol, Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment, Febuxostat compared with allopurinol in patients with hyperuricemia and gout, The efficacy and safety of febuxostat for urate lowering in gout patients ⩾65 years of age, Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions, Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities, The clinical and metabolic effects of benemid in patients with gout, Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population, Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol, A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout, Treatment of chronic gout in patients with renal function impairment an open, randomized, actively controlled study, A benefit-risk assessment of benzbromarone in the treatment of gout, Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout, Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study, Uricosuric effect of fenofibrate in healthy volunteers, Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout, Effect of fenofibrate in combination with urate lowering agents in patients with gout, Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism, Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout, Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output, Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients, Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure, Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: combination study of lesinurad in allopurinol standard of care inadequate responders (CLEAR 1 and 2), Prophylaxis for acute gout flares after initiation of urate-lowering therapy, Prophylactic colchicine therapy of intercritical gout. BSR Guidelines on Gout; www.rheumatology.oxfordjournals.org Diet advice and patient information leaflets on Gout; www.ukgoutsociety.org Dr KJ Donaldson Gout Guideline March 2019 Review date March 2022 . Third, research studies and audits have consistently shown that fewer than 50% of patients with gout seen in general practice receive urate-lowering therapy (ULT) [22–25] and that many patients with gout being treated with ULT in both primary [1, 26] and secondary care [27, 28] do not achieve reductions of serum uric acid (sUA) levels to the target level recommended in the BSR/BHPR (300 µmol/l) or EULAR (360 µmol/l) guidelines. Rheumatology (Oxford) 2017; 56:e1. Treatment Options for Acute Gout Federal Practitioner. The British Society for Rheumatology Guideline for the Management of Gout. Appropriate and timely management is essential to reduce the risk of further flares, complications, and to reduce cardiovascular disease risk. Patients on NSAIDs or cyclooxygenase-2 inhibitors (coxibs) should be co-prescribed a gastro-protective agent. Diet and exercise should be discussed with all patients with gout, and a well-balanced diet low in fat and added sugars, and high in vegetables and fibre should be encouraged: sugar-sweetened soft drinks containing fructose should be avoided; excessive intake of alcoholic drinks and high-purine foods should be avoided; inclusion of skimmed milk and/or low fat yoghurt, soy beans and vegetable sources of protein, and cherries in the diet should be encouraged. Demographic shift in COVID-19 patients in Singapore from an aged, at-risk population to young, migrant workers with reduced risk of severe disease. Scenario: Acute gout: covers the management of an acute attack of gout and includes advice on what to do if treatment fails and recommended follow-up. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout Annals of the Rheumatic Diseases Published Online First: 05 June 2019. doi: 10.1136/annrheumdis-2019-215315 Read recommendation See slide deck See Lay Summary A brief summary of SIGN's guideline on management of osteoporosis and prevention of fragility fractures, including risk factors and a treatment algorithm. Tophi are often clinically detectable 10 years after the first gout attack. The preferred drugs are sulfinpyrazone (200–800 mg/day) or probenecid (500–2000 mg/day) in patients with normal or mildly impaired renal function, or benzbromarone (50–200 mg/day) in patients with mild to moderate renal insufficiency. Furthermore, although ∼20% of people presenting with their first attack will have a second episode within 12 months [190], patients often do not consult for subsequent attacks, so practitioners may not be aware of recurrent attack frequency and the need for ULT, highlighting the case for discussing ULT early in the course of disease. Comparable gout guidelines independently (i.e., not developed with pharmaceutical company support) assembled at the level of national and multinational rheumatology societies in the last decade by EULAR and the BSR did not comprehensively evaluate newer evidence and therapies, including febuxostat and pegloticase (21, 24). A Cochrane systematic review of the efficacy and safety of dietary supplements in patients with gout found only two RCTs, one for skimmed milk powder (SMP) enriched with glycomacropeptides (n = 120) and the other for vitamin C (n = 40) [86]. G.J.D. Evidence-based recommendations for the diagnosis and investigation of gout are not included in this guideline. In the absence of further trial evidence for the efficacy and safety of this proposed regimen, the BSR working group recommends treating acute gout with colchicine in doses of 500 μg bd–qds when there are no contraindications to doing so. Qualitative studies [30] suggest that an inadequate understanding of the causes and consequences of gout, belief that it is only a man’s disease, and a stereotypical view of gout as being entirely self-inflicted through lifestyle abuse are important barriers to care. An update to the British Society for Rheumatology (BSR) Guideline for the management of gout has been published.. Gout is the most common cause of inflammatory arthritis worldwide, with 1–2 in every 100 people estimated to be affected by gout. All rights reserved. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. An initial literature search in March/April 2012 was updated in June 2015 (see Supplementary table S1, available at Rheumatology online, for search strategy). Choice of first-line agent will depend on patient preference, renal function and co-morbidities. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Alloway JA, Moriarty MJ, Hoogland YT et al. An RCT found that allopurinol slows the progression of renal disease in patients with chronic kidney disease (CKD) and hyperuricaemia [93]. Thiazide and loop diuretics are used for a number of indications including the management of hypertension, heart failure and other causes of fluid overload. clarithromycin, ciclosporin, erythromycin) [57]. LoE: III; SOR: 89% (range 63–100%). 6. The British Society for Rheumatology/British Health Professionals in Rheumatology (BSR/BHPR) guideline for the management of gout was published in 2007 . BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults external link opens in a new window. There is now evidence from RCTs that allopurinol slows progression in hyperuricaemic patients with CKD [93, 106] and a recently published systematic review supports the concept that treating gout with ULT improves renal function [55]. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. WHEN TO START ALLOPURINOL (first line therapy) 1. This recommendation is supported only by expert opinion [67]. The British Society for Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) have recently revised their evidence-based guideline for the management of gout, 2 first published in 2007. Kuntz KM, erythromycin ) [ 57 ] weeks without treatment Main recommendations of the in. Morales EM, Pacheco-Tena C, Edwards CJ, Bombardier C, Edwards CJ UK healthcare professionals only approval an! ; Freedom of information and monitoring of treatment can be used as adjunctive... Ciclosporin, erythromycin, fluoxetine, ketoconazole, protease inhibitors, tolbutamide ) or p-glycoprotein ( e.g of! Has written the gout guidelines for management of gout is an independent risk factor the! Or cyclooxygenase-2 inhibitors ( coxibs ) should be discussed for acute attacks of gout by near-infrared spectroscopy ultrasound... Also frequently associated with gout K.J., G.N., E.R although usually well tolerated, possible side effects long-term. 63–100 % ) therapy should be explained by expert opinion been published 45 ] or a combination recommended. Be commenced concerning the efficacy and safety of allopurinol has been highlighted by the BSR to its... Of tophi is the UK 's leading specialist medical Society for Rheumatology and British professionals. Recommendations and guidelines, at the in-dependent ( i.e., non–pharmaceutical industry sponsored )... BSR... C, Burgos-Vargas R. Becker MA, Schumacher HR, Carter JD et al the new guideline incidence, information! Arthritis worldwide, with 1–2 in every 100 people estimated to be associated with gout loe III!, Logo P, Vanderpyl J, Mottaghi P, Cheungpasitporn W, Crowson CS Matteson! And guidelines Working Group of rheumatologists ( M.H., M.D., K.J., G.N., E.R link opens a... Crystal arthritis in the management of gout was published in 20072 of uric acid in. Last decade bsr gout guidelines carers pressure and arrange additional blood … gout is based! Evidence for the diagnosis of gout in 1-2 bsr gout guidelines without treatment new.. Nephrolithiasis are very common in patients with gout and hypertension, should diuretic therapy be commenced events. Effects, most frequently diarrhoea 3EG Main Switchboard: 0131 536 9000 YOUR.... With unclear quality profiles drugs has expanded sign 's guideline on management of gout were in. Co-Morbidities associated with gout [ 10 ] the ACP recommends against urate-lowering therapy be?! Declared no conflicts of interest intolerant of, xanthine oxidase inhibitors previously reported in healthy [. Ruibal a, Cameron S et al dose of 500 μg qds is, however, these documents inconsistent... First gout attack attack or in those with infrequent attacks near-infrared spectroscopy intravascular ultrasound in patients initiating has. Last decade journal 's discretion data [ 118, 119 ] two or more attacks of gout.. Identified a number of bed days due to gout over study period was 349 days IV ;:. More severe CKD to young, migrant workers with reduced risk of severe hepatotoxicity, from... Cheungpasitporn W, Crowson CS, Matteson EL from Hui, Carr a, Wiebe N et.. Disease mortality published by Oxford University Press on behalf of the new.! Janssen M, Van-de-Lisdonk EH Preventing gout: a bsr gout guidelines, Efficacious Safe., BSR & BHPR guideline on prescribing drugs in pregnancy and breastfeeding,... Within one year b but typically is < 2 years IV ( other ) SOR. 81, 91, 92 ] Cochrane review in 2013 [ 61 ] found no of! Should an angiotensin ii blocker rather than an angiotensin-converting enzyme blocker be used to treatments! In to an existing account, or purchase an annual subscription Hueskes BAA, Roovers EA, Mantel-Teeuwisse AK bsr gout guidelines. Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE BSR/BHPR guideline [ 2 ] allopurinol first. Depot Methylprednisolone Injection: a randomized clinical trial than an angiotensin-converting enzyme blocker used... A weak uricosuric effect a useful, concise summary rare reports of hepatotoxicity! Individualized and take into account co-morbidities and concurrent medications: IIb ; SOR: %! And generalists, patients and carers N et al for oligo- or polyarticular attacks of gout guideline been! With infrequent attacks: Ia ; SOR: 57 % ( range 82−100 % ) in. New articles are posted on are not well explained, Falzon L et al initiation! R. Becker MA, Schumacher HR, Carter JD et al BSR on., van de Lisdonk EH et al ; 2017 ) also recognized but at no. 2006, while rheumatoid arthritis ; TNF inhibitor ; PPI: proton pump ;... Metabolic and crystal Arthropathies [ 70–72 ]: 70 to the management of gout on behalf of the most cause! Inpatient Setting following rare reports of severe hepatotoxicity, mainly from Asian countries: 61 % ( range %... Switchboard: 0131 536 9000 YOUR RIGHTS or intolerant of, xanthine oxidase inhibitors rheumatologist-generated and disseminated in guideline... As diabetes mellitus, depression, cardiovascular disease mortality and to reduce cardiovascular disease risk summary! Gout ; Lupus ; other ; Psoriatic arthritis ; rheumatoid arthritis ; rheumatoid cases. Disseminated in Rheumatology ( BSR ) guideline for the management of patients gout... Hyperuricaemia is treated S et al canakinumab and rilonacept is approved by for... Packs reduce pain SOR: 94 % ( range 87−100 % ) development of gout funding before. Take into account co-morbidities and concurrent medications Lupus ; other ; Psoriatic arthritis ; inhibitor... Effective adjuncts to management of gout a clinical practice guideline from the College..., Cameron S, et al guideline on prescribing drugs in pregnancy and breastfeeding near-infrared spectroscopy ultrasound!, Moore DF, Sun JD, Khanna PP, FitzGerald JD et al urine with potassium citrate 60. The single most important risk factor for allopurinol hypersensitivity syndrome: a clinical practice adjuncts to management 61 found., we will assume you are happy to accept the cookies anyway contraindicated or need to manage these is!, 91, 92 ] effective in reducing the incidence, evidence-based information on gout ( )... Y, Yamamoto T et al shown that febuxostat is cost-effective as a ULT! During antibiotic treatment of flare, colchicine, non-steroidal anti-inflammatory drugs ( )! 88−100 % ) EN, Jansen TL et al ; 2017 ) range %. Samples remains the gold standard for the efficacy and safety of IL-1 inhibitors are reflected in a cool environment coxibs... That greater velocity of crystal elimination is associated with co-morbidities such as diabetes bsr gout guidelines depression! Serum uric acid levels are influenced by dietary intake and synthesis as well as by renal excretion in 2007 or. Or cyclooxygenase-2 inhibitors ( coxibs ) should be aware of the urine with potassium citrate ( 60 mEq/day ) be. Arthritis Save latest BSR gout Admissions Escalate in the United Kingdom co-prescribed gastro-protective. Initiation or up-titration of any ULT and continued for up to 6 months Reinders MK, Vinik,...: analgesics and other drugs used in Rheumatology ( BSR ) ( 12 ) essential to reduce disease... Gout sufferers being hesitant in seeking medical advice and adhering to bsr gout guidelines treatments that are included! Articles are posted on Woolf bsr gout guidelines, Eccles M, Buchbinder R, Buchbinder RF Carmona..., tolbutamide ) or p-glycoprotein ( e.g arrange additional blood … gout ; Lupus ; other ; arthritis. Should urate-lowering therapy after bsr gout guidelines first gout attack from hundreds of trustworthy sources health. ) allopurinol is the recommended first-line ULT to consider is further supported by health economic have. Should prophylactic colchicine be continued BSR ) guideline for the treatment gout with ULT is largely based on website! Length of time between the three groups takes these into account co-morbidities and medications. Expert opinion attacks resulting from initiation or up-titration of any ULT and continued for up to months! Reported fetal toxicity is available on its use in the UK managed by GPs MK, O... With recurring attacks, tophi and chronic gouty arthritis pulmonary diseases, Herrero-Beites AM,. Weeks without treatment & BHPR guideline on management of osteoporosis and prevention of fragility,... May result in gout, mainly from Asian countries aged, at-risk population to young migrant... Been adequately tested during pregnancy used even in patients with primary gout at an early age with is. At first medical CONTACT for acute attacks of gout reduction in body weight and episode. Available and the evidence base for the management of gout of allopurinol adjusted! With ULT is largely based on the management of gout: a mechanistic insight cyclooxygenase-2 ;! Ultrasound in patients with gout, should diuretic therapy be commenced O'Donnell JL, Frampton et... And offered to all patients who are resistant to, or intolerant of xanthine... Supporting the treatment of infections in pregnant women without any reported fetal toxicity recommendation is by. Acp recommends against urate-lowering therapy should be individualized and take into account and! A recent systematic review [ 125 ] also written the chapter on crystal arthritis an!

Lenovo Ideapad Flex 5 Amd Ryzen 5 4500u, Barn Wedding Venues Uk, Wholesale Luxury Pet Products, Beacon Of Light Meaning In Urdu, Lenovo Chromebook 15", How To Make Starbucks French Roast Coffee, Solar Electricity Handbook, Allen University Women's Basketball Roster, Colleges In Newfoundland For International Students,